ComplexINC: Kick-off Meeting in Martinsried, Munich
23 January 2012
Germany
The Kick-Off Meeting was chaired by the Deputy Coordinator Dr. Ismail Moarefi, Executive Director of Science & Technology and legal representative of Crelux GmbH, together with the Coordinator Dr. Imre Berger, EMBL Group Leader at the Genome Biology Unit at EMBLE, Grenoble.
ComplexINC is a four-year Collaborative Project funded by the EC under the 7th Framework Programme of the European Union. With an overall budget of 5,9 Mio €, ComplexINC aims to design, validate and roll-out new and powerful tools, high-throughput methods and technologies for the production of complex biologics. This project has an international, intersectoral and innovative consortium combining world-leading expertise at European academic research institutions and successful SMEs:
- European Molecular Biology Laboratory Grenoble, France (Coordinator)
- CRELUX GmbH, Germany (Deputy coordinator)
- Helmholtz Centre for Infection Research, Germany
- Instituto de Biologia Experimental e Tecnológica, Portugal
- Agencia Estatal Consejo Superior de Investigaciones Científicas, Spain
- Bioingenium, Spain
- European Research and Project Office GmbH, Germany
Background:
In addition to their essential role as tools for drug discovery, complex biologics themselves are increasingly being employed as medicines. Indeed, the fastest growing new drug segment in the pharmaceutical industry are therapeutic proteins. They are predicted to dominate the next generation of drugs. Nevertheless, sophisticated high-performance platforms for the production of most complex biologics are distinctly lacking today. Based on the leading expertise and innovative drive of the partners, ComplexINC will address this urgent and imposing bottleneck, by providing new and sophisticated tools and technologies, to overcome the challenge of complex biologics production in drug discovery and therapy for the 21st century.
Aims of the project:
ComplexINC covers the entire domain of eukaryotic production technologies from gene to protein product; in addition, it combines cutting-edge approaches in innovative production system development which are among the most advanced to date. Putting in place the technological innovations and tool-kits obtained in ComplexINC, the research results will have a dramatic impact on the accessibility of proteins, protein complexes and complex biologics. The attained innovations will display tailor-made properties geared towards applications in drug discovery and in the treatment of human diseases, with immediate benefits to industry and the health of Europe’s citizens by cost-effective and powerful new drugs.
ComplexINC is a four-year Collaborative Project funded by the EC under the 7th Framework Programme of the European Union. With an overall budget of 5,9 Mio €, ComplexINC aims to design, validate and roll-out new and powerful tools, high-throughput methods and technologies for the production of complex biologics. This project has an international, intersectoral and innovative consortium combining world-leading expertise at European academic research institutions and successful SMEs:
- European Molecular Biology Laboratory Grenoble, France (Coordinator)
- CRELUX GmbH, Germany (Deputy coordinator)
- Helmholtz Centre for Infection Research, Germany
- Instituto de Biologia Experimental e Tecnológica, Portugal
- Agencia Estatal Consejo Superior de Investigaciones Científicas, Spain
- Bioingenium, Spain
- European Research and Project Office GmbH, Germany
Background:
In addition to their essential role as tools for drug discovery, complex biologics themselves are increasingly being employed as medicines. Indeed, the fastest growing new drug segment in the pharmaceutical industry are therapeutic proteins. They are predicted to dominate the next generation of drugs. Nevertheless, sophisticated high-performance platforms for the production of most complex biologics are distinctly lacking today. Based on the leading expertise and innovative drive of the partners, ComplexINC will address this urgent and imposing bottleneck, by providing new and sophisticated tools and technologies, to overcome the challenge of complex biologics production in drug discovery and therapy for the 21st century.
Aims of the project:
ComplexINC covers the entire domain of eukaryotic production technologies from gene to protein product; in addition, it combines cutting-edge approaches in innovative production system development which are among the most advanced to date. Putting in place the technological innovations and tool-kits obtained in ComplexINC, the research results will have a dramatic impact on the accessibility of proteins, protein complexes and complex biologics. The attained innovations will display tailor-made properties geared towards applications in drug discovery and in the treatment of human diseases, with immediate benefits to industry and the health of Europe’s citizens by cost-effective and powerful new drugs.